Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Jazz Pharmaceuticals plc’s stock clocked out at $163.68, up 1.58% from its previous closing price of $161.13. In other words, the price has increased by $1.58 from its previous closing price. On the day, 0.9 million shares were traded. JAZZ stock price reached its highest trading level at $164.385 during the session, while it also had its lowest trading level at $160.66.
Ratios:
To gain a deeper understanding of JAZZ’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.86 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.44. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152.
UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 09 ’25 when Henderson Mary Elizabeth sold 2,238 shares for $169.51 per share. The transaction valued at 379,366 led to the insider holds 19,508 shares of the business.
MARY ELIZABETH HENDERSON bought 2,238 shares of JAZZ for $379,365 on Dec 09 ’25. On Dec 05 ’25, another insider, Carr Patricia, who serves as the SVP, Chief Accounting Officer of the company, sold 4,660 shares for $171.20 each. As a result, the insider received 797,783 and left with 7,012 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 9946034176 and an Enterprise Value of 13328924672. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.19. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.39 while its Price-to-Book (P/B) ratio in mrq is 2.51. Its current Enterprise Value per Revenue stands at 3.206 whereas that against EBITDA is 8.289.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.26, which has changed by 0.31042612 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 0.97%, while the 200-Day Moving Average is calculated to be 27.05%.
Shares Statistics:
It appears that JAZZ traded 1.11M shares on average per day over the past three months and 1184710 shares per day over the past ten days. A total of 60.74M shares are outstanding, with a floating share count of 57.98M. Insiders hold about 4.59% of the company’s shares, while institutions hold 100.67% stake in the company. Shares short for JAZZ as of 1767139200 were 5363382 with a Short Ratio of 4.84, compared to 1764288000 on 4974908. Therefore, it implies a Short% of Shares Outstanding of 5363382 and a Short% of Float of 10.2.
Earnings Estimates
The performance of Jazz Pharmaceuticals plc (JAZZ) in the stock market is under the watchful eye of 14.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $4.15, with high estimates of $5.96 and low estimates of $2.59.
Analysts are recommending an EPS of between $8.52 and $7.73 for the fiscal current year, implying an average EPS of $8.07. EPS for the following year is $21.85, with 14.0 analysts recommending between $26.91 and $18.67.
Revenue Estimates
In. The current quarter, 14 analysts expect revenue to total $1.15B. It ranges from a high estimate of $1.2B to a low estimate of $1.11B. As of. The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 14 analysts are estimating revenue of $994.76M. There is a high estimate of $1.12B for the next quarter, whereas the lowest estimate is $899M.
A total of 16 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.27B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 16 analysts’ estimates, the company’s revenue will be $4.5B in the next fiscal year. The high estimate is $4.79B and the low estimate is $4.12B.
